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Abstract
Recent evidence has shown that structural magnetic resonance imaging (MRI) is
an effective tool for Alzheimer’s disease (AD) prediction and diagnosis. While tradi-
tional MRI-based diagnosis uses images acquired at a single time point, a longitudinal
study is more sensitive and accurate in detecting early pathological changes of the AD.
Two main difficulties arise in longitudinal MRI-based diagnosis: (1) the inconsistent
longitudinal scans among subjects (i.e., different scanning time and different total
number of scans); (2) the heterogeneous progressions of high-dimensional regions of
interest (ROIs) in MRI. In this work, we propose a novel feature selection and es-
timation method which can be applied to extract features from the heterogeneous
longitudinal MRI. A key ingredient of our method is the combination of smoothing
splines and the l1-penalty. We perform experiments on the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) database. The results corroborate the advantages of the
proposed method for AD prediction in longitudinal studies.
Keywords: Smoothing splines; High dimensionality; Heterogeneous data; Longitudinal
analysis; Alzheimer’s disease; Magnetic resonance imaging.
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1 Introduction
Alzheimer’s Disease (AD) is the most common cause of dementia in the aged population
[12]. In order to prevent disease progression and take therapeutic treatment in the earliest
stage, it is vital to identify AD-related pathological biomarkers of progression and diagnose
early-stage AD. A considerable amount of research has been devoted to the use of structured
magnetic resonance imaging (MRI) for early-stage AD diagnosis; e.g., [6, 7]. The structural
MRI provides measures of cerebral atrophy and it is shown to be most closely coupled with
clinical symptoms in AD [5].
Figure 1: Illustration of heterogenous longitudinal data with p covariates.
Most work in the literature focus on the cross-sectional study with MRI collected at one
single time point; see, e.g., [1, 8, 20]. However, the cross-sectional study could be insen-
sitive to early pathological changes. As an alternative, longitudinal analysis of structural
abnormalities has recently attracted attentions [2, 24, 26]. Most of these existing longitudi-
nal studies focus on the atrophy of a few well-known biomarkers such as the hippocampus,
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entorhinal cortex, and ventricular cortex. However, these prespecified ROIs may be insuf-
ficient to capture the full morphological abnormality pattern of the brain MRI. Besides
it, a few other issues remain as challenges in the longitudinal analysis. First, longitudinal
scans across subjects are usually inconsistent. For example, subjects could have different
scanning time and different total number of scans. Second, the total number of ROIs in
the brain is large compared with the number of subjects, which poses a challenge to select
AD-rated longitudinal biomarkers from the whole brain. Third, the rates of longitudinal
change in different ROIs are different and this heterogeneity should be accounted by the
modeling of progression.
The goal of this paper is to identify important AD-related ROIs in the whole brain
MRI with longitudinal MRI data and use the selected ROIs for AD prediction. Specifi-
cally, we use the varying coefficient model [3] to characterize the heterogeneous changes
of different ROIs in structural MRI. This model also allows a nonlinear functional mod-
eling between MRI and clinical cognition functions. We propose a novel feature selection
method by combining the smoothing splines and a l1-penalty, which can simultaneously
select and estimate AD-related ROIs. We provide an efficient algorithm to implement the
proposed feature selection method. Then the prediction is performed based on the selected
longitudinal features and estimated varying coefficients. Our method is robust to the in-
consistency among longitudinal scans and is adaptive to the heterogeneity of changes in
different ROIs. The use of varying coefficient models is motivated by the hypothetical
AD dynamic biomarkers curves proposed by [6, 7], where their principle is that the rates
of change over time for MRI and clinical cognition functions are in a temporally ordered
manner. Hence, the functional relationship between the atrophy of MRI and the change in
clinical cognition functions must be nonlinear in time.
To evaluate our method, we perform experiments using data from the Alzheimer’s Dis-
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ease Neuroimaging Initiative (ADNI). We predict future clinical changes of mild cognitive
impairment (MCI) subjects with brain MRI data. The MCI is a prodromal stage of AD.
The prediction of clinical changes help to determine whether a MCI subject will convert
into AD at a future time point, which is vital for early diagnosis of AD.
Main differences between this paper and existing longitudinal studies in [2, 24, 26] are
as follows.
• Different feature representations. We use the varying coefficient model to characterize
nonlinear and smooth progression of longitudinal features, which is motivated by
clinical findings and the dynamic biomarker curve in [6, 7]. On the contrary, [2, 24, 26]
use linear representations for features.
• Different scalability to heterogenous longitudinal scans. Different from [2, 24, 26],
our method does not require same scanning times and a same number of scans across
samples.
• Different feature selections. We proposed a novel feature selection method by com-
bining smoothing splines with a l1-penalty, which allows to simultaneously select and
estimate features. This is different from the two-step method in [26] by doing the
selection and estimation separately and [2, 24] by only using pre-selected features.
The rest of the paper is organized as follows. We introduce our method in Section 2. We
give experiment results in Section 3. The conclusion remarks and discussions are given in
Section 4. Additional material and proofs are relegated to Appendix in the supplementary
material.
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2 Methodology
The varying coefficient model [3] can describe time-dependent covariate effects on the re-
sponses. Given scaled time t ∈ [0, 1], the response functional Y (·) is related to covariates
X1(·), . . . , Xp(·) through
Y (t) = b+
p∑
j=1
βj(t)Xj(t) + ε(t), b ∈ R, (2.1)
where the centered noise process ε(·) is independent of Xj(·)s. The model (2.1) allows a
nonlinear relationship between Xj(·)s and Y (·) be letting the coefficients βj(·)s vary on
t. On the other hand, (2.1) has an additive structure on covariates Xj(·)s, which enables
efficient estimations of coefficients βj(·)s.
In practice, data are obtained for subject i = 1, . . . , n at time tiν , where ν = 1, 2, . . . ,mi,
and 0 ≤ ti1 ≤ ti2 ≤ · · · ≤ timi ≤ 1. Note that mi and tiνs are allowed to be different for
different subjects i. Denote Xj(tij) = xij and let yiν be the response for subject i at time
tiν , then (2.1) implies
yiν = b+
p∑
j=1
βj(tiν)xij(tiν) + ε(tiν), b ∈ R. (2.2)
The structure of heterogenous longitudinal data is illustrated in Figure 1, where some sub-
jects could have missing feature values at certain time point. The number of covariates p
in (2.2) can be larger than the sample size n, and then (2.2) becomes a high-dimensional
model. Since some covariates might be irrelevant with the response, we want to select im-
portant covariates Xj(·)s based on data (2.2) and use the selected covariates for prediction.
We propose a new method to simultaneously select covariates and estimate their corre-
sponding varying coefficients as follows. Assume that varying coefficients β1(·), β2(·), . . . , βp(·)
reside in a reproducing kernel Hilbert space (RKHS) (HK , ‖ · ‖HK ) with the reproducing
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kernel K(·, ·) [22]. Find β1(·), β2(·), . . . , βp(·) ∈ HK and b ∈ R to minimize
1
N
n∑
i=1
mi∑
ν=1
[
yiν − b−
p∑
j=1
βj(tiν)xij(tiν)
]2
+ λ
p∑
j=1
‖βj‖HK , (2.3)
where N =
∑n
i=1mi and ‖ · ‖HK is the RKHS norm. The first term in (2.3) measures the
goodness of data fitting and the second term merits the selection property by the l1-like
penalty
∑p
j=1 ‖βj‖HK . We first provide the following theorem to justify the existence of
minimizer for (2.3).
Theorem 2.1. There exists a minimizer of (2.3) that is in the domain β1(·), . . . , βp(·) ∈ HK
and b ∈ R.
The proof of this theorem is given in Appendix C. The variable selection method (2.3)
is new in the literature and (2.3) is efficient for optimization since it is convex in βj(·)s and
it has only one tuning parameter λ. We provide an algorithm in Appendix D.
The following theorem gives further insights into (2.3) that it is indeed a combination
of the smoothing splines [22] and the Lasso [17].
Theorem 2.2. Consider the following optimization problem. Find β1(·), . . . , βp(·) ∈ HK
and θ1, . . . , θp, b ∈ R to minimize
1
N
n∑
i=1
mi∑
ν=1
[yiν − b−
p∑
j=1
βj(tiν)xij(tiν)]
2 + τ0
p∑
j=0
θ−1j ‖βj‖2HK + τ1
p∑
j=0
θj,
s.t. θj ≥ 0, j = 0, 1, . . . , p,
(2.4)
where τ0 is a constant and τ1 is a tuning parameter. Let τ1 = λ4/(4τ0). The following
equivalence holds.
1) If (β̂0, β̂1(·), . . . , β̂p(·)) minimizes (2.3), by letting θ̂j = τ 1/20 τ−1/21 ‖β̂j‖HK , we have that
(θ̂1, . . . , θ̂p; β̂0, β̂1(·), . . . , β̂p(·)) minimizes (2.4).
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2) If there exists (θ̂1, . . . , θ̂p; β̂0, β̂1(·), . . . , β̂p(·)) minimizes (2.4), then (β̂0, β̂1(·), . . . , β̂p(·))
minimizes (2.3).
We give the proof of this theorem in Appendix E. Note that (2.4) is a combination of
the smoothing splines and the Lasso since the first two terms:
1
N
n∑
i=1
mi∑
ν=1
[yiν − b−
p∑
j=1
βj(tiν)xij(tiν)]
2 + τ0
p∑
j=0
θ−1j ‖βj‖2HK + τ1
p∑
j=0
θj
is actually the same as the smoothing splines in nonparametric statistics [22], and the last
term
τ1
p∑
j=0
θj
is actually the same as the Lasso penalty [17] for the weights θjs.
Let Xj1 , Xj2 , . . . , Xjs be s of selected features by (2.3), 1 ≤ j1 ≤ j2 ≤ · · · ≤ js ≤ p,
and β̂j1 , β̂j2 , . . . , β̂js be the corresponding estimated varying coefficients by (2.3). Then the
prediction model for a new subject with features X∗j1(t), X
∗
j2
(t), . . . , X∗js(t) at time t is
f̂ ∗(t) = β̂j1X
∗
j1
(t) + β̂j2X
∗
j2
(t) + · · ·+ β̂jsX∗js(t).
3 Experiment Results
In this section, we predict future clinical changes of MCI subjects with real data from the
ADNI database. A detailed description of the ADNI database is relegated to Appendix A.
The MCI is a prodromal stage of AD. Generally, some MCI subjects will convert into AD
after certain time (i.e., MCI converters, MCI-C for short), while others will not convert
(i.e., MCI non-converters, MCI-NC for short) [26]. The prediction of clinical change in a
MCI subject help to determine whether the subject will convert into AD at a future time
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Table 1: Demographics of ADNI subjects studied here
MCI-C MCI-NC
(n = 74) (n = 98)
Male/Female 44 / 30 61 / 37
Age (years) 73.03 ± 6.65 74.35 ± 7.47
Edu. (years) 15.51 ± 3.05 15.59 ± 3.07
point, which is a central task for the early diagnosis of AD. We summarize the baseline
demographic information of ADNI subjects studied here in Table 1.
The preprocessing steps for brain MR imaging used here are described in Appendix B.
Specifically, we have total 324 ROIs for each imaging. For MCI subjects, MRI scans were
performed at baseline (bl), 6 months (M06), one year (M12), 18 months (M18), two years
(M24), three years (M36), and four years (M48). However, some subjects may miss a few
visit times and hence they do not have MRI scans at these time points. We choose n = 172
MCI subjects who have M48 imaging data. Table 2 lists the distributions of visit times
for these 172 MCI subjects, where, e.g., 6 of MCI-C subjects make at most 3 visits among
the scheduled six times (bl, M06, M12, M18, M24, M36) such that they have at most 3
longitudinal MRI scans.
Our goal is to use longitudinal information (from bl up to M36) to predict the clinical
changes of MCI subjects at M48. Since the empirical evidences suggest that the rates of
change over time for structural MRI and clinical cognition functions are in a temporally or-
dered manner (see, e.g., [6, 7]), a nonlinear modeling for the functional relationship between
the atrophy of MRI and the change in clinical cognition functions is necessary. Hence, the
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Table 2: Distribution of visit times for ADNI subjects studied here
MCI-C MCI-NC
(n = 74) (n = 98)
≤ 3 scans 6 6
4 scans 8 14
5 scans 15 33
6 scans 45 45
varying coefficient model (2.1) is used. We choose the Alzheimer’s Disease Assessment
Scale – Cognitive Subscale (ADAS-Cog) as the response clinical cognitive test score Y (·)
and it ranges from 70 (severe cognitive impairment) to 0 (no cognitive impairment). The
ADAS-Cog measures disturbances of memory, language, and other cognitive abilities. The
covariates Xj(·)s include 324 MR imaging ROIs and 3 demographic covariates: age, gender,
and education years. The index t in (2.1) should be identifiable and we let t be the scaled
time relative to subjects enter the ADNI study. Figure 2 gives the flowchart of our method.
We build six models by using six different levels of longitudinal information:
• Model 1: bl.
• Model 2: bl+M06 (including subjects have missings at bl).
• Model 3: bl+M06+M12 (including subjects have missings at bl or M06).
• Model 4: bl+M06+M12+M18 (including subjects have missings at bl, M06 or M12).
9
Figure 2: Flowchart of the proposed method.
• Model 5: bl+M06+M12+M18+M24 (including subjects have missings at bl, M06,
M12 or M18).
• Model 6: bl+M06+M12+M18+M24+M36 (including subjects have missings at bl,
M06, M12, M18, or M24).
Following the flowchart in Figure 2, we first perform the feature selection method in
(2.3) for each of the six models. In each experiment, we randomly leave out half of samples
in both MCI-C and MCI-NC for prediction. For the training of each model, a 10-fold cross
validation is performed to select the tuning parameter λ in (2.3). The experiments are
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Figure 3: The prediction comparisons of our method using six levels of longitudinal data.
replicated for 100 times. We summarized the prediction results in Figure 3. It is clear that
the longitudinal data can significantly improve the prediction results compared with only
using baseline information. And the more longitudinal data included, the better prediction
will be obtained. We also observe that the prediction results for MCI-NC are slightly
better compared with MCI-C, which can be explained by the fact that MCI-NC subjects
have more stable clinical status and less varied clinical scores.
We give examples of selected feature in Figure 4. These are four ROIs that consistently
selected in Model 6 for 100 experiments. Figure 4 demonstrates the varying coefficients
of the ROIs. Specifically, gender is an important factor and different ROIs have different
functional relations with clinical functions (i.e., the maximum effect of each biomarker
varies over the course of disease progression). This confirms the evidence and hypothesis
in [15, 16] that atrophy does not affect all regions of the brain simultaneously, but perhaps
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Figure 4: Examples of selected features for Model 6.
in a sequential manner.
Figure 5: The prediction comparisons of three methods for MCI-C.
Now we compare our method (2.3) with other two state-of-the-art methods:
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Figure 6: The prediction comparisons of three methods for MCI-NC.
• The longitudinal analysis in [2] which only uses the hippocampal volume shrinkage
rate as the feature.
• The longitudinal analysis in [26] which use linear feature representations and a group
Lasso for variable selection (e.g., [25]).
Since the methods in [2, 26] require same scanning times and a same number of scans across
samples, we perform Model 1–6 for AD prediction with samples having no missing visits.
In each experiment, we randomly leave out half of samples in both MCI-C and MCI-NC
for prediction. For the training of each model, a 10-fold cross validation is performed to
select the tuning parameters in (2.3) and in [2, 26]. The experiments are replicated for 100
times. The prediction comparison results for MCI-C are summarized in Figure 5 and the
prediction comparison results for MCI-NC are summarized in Figure 6. It is clear that our
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proposed method consistently achieves better prediction performances for both MCI-C and
MCI-NC. The reason of the superior performance of our method is due to the modeling
of nonlinear progression of longitudinal features and selecting important features from the
whole brain instead of only using a prespecified feature for prediction.
4 Discussion
We study a framework to integrate longitudinal features from the structural MR images for
AD prediction based on varying coefficient models. We propose a novel variable selection
method by combining smoothing splines and Lasso, which enables simultaneous selection
and estimation and is adaptive to heterogeneous longitudinal data. To illustrate the effec-
tiveness of the proposed method, we conduct experiments with the ADNI dataset and show
that the proposed method outperforms the state-of-the-art longitudinal analysis methods.
Our work is the first in the literature to model nonlinear progressions of longitudinal
features and propose a novel effective variable selection method for the high-dimensional set-
ting. This method shows superior performance in real data AD prediction. It is promising
and easy to implement the proposed method in other longitudinal data analysis examples.
There are many interesting future directions. For example, we only use MR images for
AD prediction in this paper. It is of interest to apply the proposed method to integrate
multi-modal data including MRI, PET, and functional MRI. We expect the integration of
multi-modal information would further improve the accuracy of the AD prediction.
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Appendix
A ADNI Database Description
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was launched in 2003 by the
National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bio-
engineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical
companies, and non-profit organization, as a $60 million, five year public-private partner-
ship.
The Principal Investigator of ADNI is Michael W. Weiner, MD, VA Medical Center and
University of California – San Francisco. ADNI is the result of efforts of many coinvestiga-
tors from a broad range of academic institutions and private corporations. ADNI recruited
from over 50 sites across the U.S. and Canada. The initial phase of ADNI recruited 800
adults, aged 55 to 90 and having a study partner able to provide an independent evalua-
tion of functioning, to participate in the research. Among them, there are approximately
200 healthy control older individuals to be followed for 3 years, 400 people with MCI to
be followed for 3 years, and 200 people with early AD to be followed for 2 years. See
www.adni-info.org for up-to-date information.
The primary goal of ADNI has been to test whether serial Magnetic Resonance Imaging
(MRI), Positron Emission Tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of MCI and
early AD. Criteria for the different diagnostic groups are summarized in Table 3. Cog-
nitively healthy control (HC) subjects must have no significant cognitive impairment or
impaired activities of daily living. Clinical diagnosed Alzheimer’s disease patients (AD)
must have had mild AD and had to meet the National Institute of Neurological and Com-
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municative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association
(NINCDS/ADRDA) criteria for probable AD in [11]. The mild cognitive impairment sub-
jects (MCI) should meet defined criteria for MCI but do not meet the criteria in [11]
and the MCI subjects should have largely intact general cognition as well as functional
performance. Study subjects should have given written informed consent at the time of en-
rollment for imaging and genetic sample collection and completed questionnaires approved
by each participating sites Institutional Review Board (IRB).
Table 3: ADNI recruitment criteria of CN, MCI and AD subjects. AD: Alzheimer’s disease;
CDR: Clinical Dementia Rating; HC: Healthy controls; MCI: Mild cognitive impairment;
MMSE: Mini-Mental State Examination; Edu : years of education.
HC MCI AD
Memory complaints Absent Present Present
CDR 0 0.5 0.5-1.0
Delayed recall Logical 16 Edu:≥ 9 16 Edu:≤ 8 16 Edu:≤ 8
Memory II subscale of 8-15 Edu:≥ 5 8-15 Edu:≤ 4 8-15 Edu:≤ 4
WMSR 0-7 Edu:≥ 3 0-7 Edu:≤ 2 0-7 Edu:≤ 2
B Preprocessing of the brain MRI used here
The structural MRI used in this study are cortical gray matter volumes processed using
FreeSurfer software version 4.4 longitudinal image processing framework (https://surfer.
nmr.mgh.harvard.edu/) (“ucsffsl" file). This dataset has been used in, for example, [9, 18,
16
19]. Specifically, subjects with a 1.5-T MRI were included in the dataset where the scans
were preprocessed by certain correction methods including gradwarp, B1 calibration, N3
correction, and skull-stripping (see, e.g., [4] for detail), and the FreeSurfer 4.4 implements
the symmetric registration [13] and unbiased robust template estimation [14]. Only MRIs
which passed the quality control for all the areas were included in our study. There are
total 393 ROIs of brain MRI created by FreeSurfer 4.4 and they consist of volumes of brain
regions obtained after cortical parcellation and white matter parcellation, surface area of
the brain regions and cortical thickness of the brain regions. However, some ROIs are
missing more than 90% across all samples due to the preprocessing. In Section 3 of the
paper, we use 324 ROIs with at most 20% missing values across the preprocessed samples.
C Proof of Theorem 2.1
Denote by A(b, β1(·) . . . , βp(·)) the functional to be minimized in (2.3). It is clear that
A(b, β1(·) . . . , βp(·)) is convex and continuous in βj(·)s. Denote by J(β1(·) . . . , βp(·)) =
λ
∑p
j=1 ‖βj‖HK , and without loss of generality, we assume λ = 1. Denote by cK =
maxi,ν K
1/2(tiν , tiν) and cx = maxj,i,ν |xij(tiν)|. By Cauchy-Schwarz inequality, for any
i = 1, . . . , n, ν = 1, . . . ,mi,
|
p∑
j=1
βj(tiν)xij(tiν)| = |〈
p∑
j=1
βj(·)xij(tiν), K(tiν , ·)〉HK |
≤ ‖
p∑
j=1
βj(·)xij(tiν)‖HKK(tiν , tiν) ≤ cK‖
p∑
j=1
βj(·)xij(tiν)‖HK ≤ cKcxJ(b, . . . , βp).
(C.1)
Denote ρ = maxi,ν{y2iν + |yiν |+ 1}. Consider the set
Ω = {β1(·), . . . , βp(·) ∈ HK , b ∈ R : J(β1(·), . . . , βp(·)) ≤ ρ, |b| ≤ ρ1/2 + (cKcx + 1)ρ}.
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Since Ω is closed, convex, and bounded set, there exists a minimizer for (2.3) in Ω. Denote
the minimizer by β˜0, β˜1(·), . . . , β˜p(·). Then, A(β˜0, β˜1(·), . . . , β˜p(·)) ≤ A(0, 0, . . . , 0) < ρ. On
the other hand, for any β1(·), . . . , βp(·) ∈ HK satisfying J(β1(·), . . . , βp(·)) > ρ. It is clear
that A(b, β1(·) . . . , βp(·)) ≥ J(β1(·), . . . , βp(·)) > ρ. For any β1(·), . . . , βp(·) ∈ HK with
J(β1(·), . . . , βp(·)) ≤ ρ and |b| > ρ1/2 + (cKcx + 1)ρ, (C.1) implies that for any i = 1, . . . , n,
ν = 1, . . . ,mi,
|b+
p∑
j=1
βj(tiν)xij(tiν)− yiν | > ρ1/2 + (cKcx + 1)ρ− cKcxρ− ρ = ρ1/2.
Hence, A(b, β1(·), . . . , βp(·)) > ρ. Therefore, for any b, β1(·), . . . , βp(·) 6∈ Ω, we have that
A(b, β1(·), . . . , βp(·)) > A(β˜0, β˜1(·), . . . , β˜p(·)), where β˜0, β˜1(·), . . . , β˜p(·) is the minimizer of
(2.3). This completes the proof.
D Algorithm
This algorithm is based on Theorem 2.2 whose proof is given later in Appendix E. Consider
for any fixed θ1, . . . , θp ≥ 0. If θj = 0 for some j, then βj = 0 in the optimization (2.4).
Without less of generality, let θ1, . . . , θp > 0 and (2.4) is equivalent to the smoothing spline
type problem: find b ∈ R, β1(·), . . . , βp(·) ∈ HK to minimize
1
N
n∑
i=1
mi∑
ν=1
[yiν − b−
p∑
j=1
βj(tiν)xij(tiν)]
2 +
p∑
j=1
(τ0θ
−1
j )‖βj‖2HK . (D.1)
By the representer lemma [22], β1(·), . . . , βp(·) have a closed form expression:
βj(t) =
n∑
i=1
mi∑
ν=1
cjiνK(tiν , t), ∀j = 1, . . . , p.
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Define a mi1 ×mi2 matrix Σ(i1,i2)j by
Σ
(i1,i2)
j =

xi1j(ti11)K(ti21, ti11) · · · xi1j(ti11)K(ti2mi2 , ti11)
...
...
xi1j(ti1mi1 )K(ti21, ti1mi1 ) · · · xi1j(ti1mi1 )K(ti2mi2 , ti1mi1 )

and let Σj be a N × N (N =
∑n
i=1mi) matrix where the (i1, i2)th mi1 × mi2 matrix is
Σ
(i1,i2)
j . Define kernel matrix Σ by
Σ =
(
Σ1 Σ2 · · · Σp
)
∈ RN×N ·p.
Let the unknown coefficient vector cj be
cj =
(
cj11 · · · cj1m1 · · · cjn1 · · · cjnmn
)>
∈ RN ,
and
c =
(
{c1}> {c2}> · · · {cp}>
)>
∈ RNp.
Write the response vector y as
y =
(
y11 · · · y1m1 · · · yn1 · · · ynmn
)>
∈ RN .
Let 1N be the column vector consisting of N 1’s. Then (D.1) becomes
1
N
(y − Σc− b1N)> (y − Σc− b1N) +
p∑
j=1
(τ0θ
−1
j ){cj}>Σjcj,
which has the unique solution given as follows:
bˆ = [1>N(1N×N − ΣΣ˜−1Σ>)1N ]−1 · 1>N(1N×N − ΣΣ˜−1Σ>)y,
cˆ = Σ˜−1Σ>(y − 1N bˆ),
(D.2)
where Σ˜ = Σ>Σ +Ndiag{(τ0θ−11 )Σ1, . . . , (τ0θ−1p )Σp}.
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Note that when θ1, . . . , θp are fixed, (2.4) is equivalent to find b ∈ R, c ∈ RNp to minimize
1
N
(y − b1N −
p∑
j=0
θjΣjc
j)> · (y − b1N −
p∑
j=0
θjΣjc
j) +
p∑
j=0
(τ0θj){cj}>Σjcj. (D.3)
The minimizer of (D.3) is
b = bˆ and cj = θ−1j cˆ
j, j = 0, 1, . . . , p,
where bˆ and cˆ are given by (D.2).
On the other hand, consider when c is fixed, then the minimization of (2.4) is equivalent
to
min
θ,b
‖y −
p∑
j=0
θjΣjc
j − b1N‖2 +Nτ0
p∑
j=0
θj{cj}>Σjcj +Nτ1
p∑
j=0
θj,
s.t. θj ≥ 0, j = 0, 1, . . . , p,
which can be written as
min
θ,b
‖y −
p∑
j=0
θjΣjc
j − b1N‖2 +Nτ0
p∑
j=0
θj{cj}>Σjcj,
s.t. θj ≥ 0, j = 0, 1, . . . , p;
p∑
j=0
θj ≤M,
(D.4)
for some M ≥ 0.
Therefore, we propose the algorithm of iterating (D.3) and (D.4) for giving the mini-
mizer of (2.4). We observe in simulations that the objective function in optimization (2.4)
decreases quickly in the first iteration and after the first iteration the objective function is
close to the objective function at convergence. This motivates us to consider the following
one-step update algorithm:
1. Initialization: fix θj = 1 for j = 0, 1, . . . , p.
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2. Solve for c and b in (D.3) and tune τ0 according to the generalized cross-validation
(GCV). Fix τ0 at the chosen value in all later steps.
3. For c and b obtained in step 2, solve for θ in (D.4) with a fixed M .
4. With θ obtained in step 3, solve for c and b in (D.3).
We choose the bestM in Step 3 according to the fivefold cross-validation. In the simulations
we find that when τ0 is fixed according to step 2, the optimal M seems to be close to the
number of important components. This gives a range to determine the tuning for M .
E Proof of Theorem 2.2
Recall thatA(b, β1(·), . . . , βp(·)) denotes the functional in (2.3). LetB(θ1, . . . , θp; b, β1(·), . . . , βp(·))
be the functional in (2.4). Observe that
τ0θ
−1
j ‖βj‖2HK + τ1θj ≥ 2τ
1/2
0 τ
1/2
1 ‖βj‖HK = λ2‖βj‖HK , ∀θj ≥ 0,
and the equality in the above formula holds if and only if θj = τ
1/2
0 τ
−1/2
1 ‖βj‖HK . Therefore,
B(θ1, . . . , θp; b, β1(·), . . . , βp(·)) ≥ A(b, β1(·), . . . , βp(·)), ∀θj ≥ 0,
and the equality holds if and only if θj = τ
1/2
0 τ
−1/2
1 ‖βj‖HK for all j = 1, . . . , p. This
completes the proof.
References
[1] C. Aguilar, E. Westman, J.S. Muehlboeck, P. Mecocci, B. Vellas, M. Tsolaki, I.
Kloszewska, H. Soininen, S. Lovestone, C. Spenger, and A. Simmons, Different multi-
21
variate techniques for automated classification of MRI data in Alzheimer’s disease and
mild cognitive impairment, Psychiatry Research: Neuroimaging, 212 (2013), pp. 89–98.
[2] A. Chincarini, F. Sensi, L. Rei, G. Gemme, S. Squarcia, R. Longo, F. Brun, S. Tan-
garo, R. Bellotti, N. Amoroso, and M. Bocchetta, Integrating longitudinal information
in hippocampal volume measurements for the early detection of Alzheimer’s disease,
NeuroImage, 125 (2016), pp. 834–847.
[3] T. Hastie, and R. Tibshirani, Varying-coefficient models, Journal of the Royal Statis-
tical Society. Series B (Methodological), (1993), pp. 757–796.
[4] C.R. Jack, M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, D. Harvey, B.
Borowski, P.J. Britson, J. L. Whitwell, and C. Ward, The Alzheimer’s disease neu-
roimaging initiative (ADNI): MRI methods, Journal of Magnetic Resonance Imaging,
27 (2008), pp. 685–691.
[5] C.R. Jack, M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, D. Harvey, B.
Borowski, P.J. Britson, J. L. Whitwell, and C. Ward, Serial PIB and MRI in nor-
mal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of
pathological events in Alzheimer’s disease, Brain, 132 (2009), pp. 1355–1365.
[6] C.R. Jack, D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, R.C.
Petersen, and J.Q. Trojanowski, Hypothetical model of dynamic biomarkers of the
Alzheimer’s pathological cascade, The Lancet Neurology, 9 (2010), pp. 119–128.
[7] C.R. Jack, D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, P.S. Aisen, L.M.
Shaw, P. Vemuri, H.J. Wiste, and S.D. Weigand, Tracking pathophysiological processes
in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers, The
Lancet Neurology, 12 (2013), pp. 207–216.
22
[8] M. Liu, D. Zhang, and D. Shen, Relationship induced multi-template learning for di-
agnosis of Alzheimer’s disease and mild cognitive impairment, IEEE Transactions on
Medical Imaging, 35 (2016), pp. 1463–1474.
[9] L. Mah, M.A. Binns, D.C. Steffens, and Alzheimer’s Disease Neuroimaging Initiative,
Anxiety symptoms in amnestic mild cognitive impairment are associated with medial
temporal atrophy and predict conversion to Alzheimer disease, The American Journal
of Geriatric Psychiatry, 23 (2015), pp. 466–476.
[10] L.K. McEvoy, D. Holland, D.J. Hagler, C. Fennea-Notestine, J.B. Brewer, and A.M.
Dale, Mild cognitive impairment: baseline and longitudinal structural MR imaging
measures improve predictive prognosis, Radiology, 259 (2011), pp. 834–843.
[11] G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stad-
lan, Clinical diagnosis of Alzheimer’s disease Report of the NINCDS-ADRDA Work
Group* under the auspices of Department of Health and Human Services Task Force
on Alzheimer’s Disease, Neurology, 34 (1984), pp. 939.
[12] M. Prince, R. Bryce, E. Albanese, A. Wimo, W. Ribeiro, and C.P. Ferri, The global
prevalence of dementia: a systematic review and metaanalysis, Alzheimer’s & Demen-
tia, 9 (2013), pp. 63–75.
[13] M. Reuter, H.D. Rosas, and B. Fischl, Highly accurate inverse consistent registration:
a robust approach, Neuroimage, 53 (2010), pp. 1181–1196.
[14] M. Reuter, N.J. Schansky, H.D. Rosas, and B. Fischl, Within-subject template estima-
tion for unbiased longitudinal image analysis, Neuroimage, 61 (2012), pp. 1402–1418.
23
[15] M.R. Sabuncu, R.S.. Desikan, J. Sepulcre, B.T.T. Yeo, H. Liu, N.J. Schmansky, M.
Reuter, M.W. Weiner, R.L. Buckner, and R.A. Sperling, The dynamics of cortical and
hippocampal atrophy in Alzheimer disease, Archives of neurology, 68 (2011), pp. 1040–
1048.
[16] N. Sabuncu, D. Tosun, P.S. Insel, G.C. Chiang, D. Truran, P.S. Aisen, C.R. Jack,
M.W. Weiner, and Alzheimer’s Disease Neuroimaging Initiative, Nonlinear time course
of brain volume loss in cognitively normal and impaired elders, Neurobiology of aging,
33 (2012), pp. 845–855.
[17] R. Tibshirani, Regression shrinkage and selection via the lasso, Journal of the Royal
Statistical Society. Series B (Methodological), (1996), pp. 267–288.
[18] J.B. Toledo, X. Da, M.W. Weiner, D.A. Wolk, S.X. Xie, S.E. Arnold, C. Davatzikos,
L.M. Shaw, J.Q. Trojanowski, and Alzheimer’s Disease Neuroimaging Initiative, CSF
Apo-E levels associate with cognitive decline and MRI changes, Acta neuropathologica,
127 (2014), pp. 621–632.
[19] D. Tosun, N. Schuff, L.M. Shaw, J.Q. Trojanowski, and M.W. Weiner, Relationship
between CSF biomarkers of Alzheimer’s disease and rates of regional cortical thinning
in ADNI data, Journal of Alzheimer’s Disease, 26 (2011), pp. 77–90.
[20] N. Tzourio-Mazoyer, B. Landeau, D. Papathanassiou, F. Crivello, O. Etard, N. Del-
croix, B. Mazoyer, and M. Joliot, Automated anatomical labeling of activations in SPM
using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, Neu-
roimage, 15 (2002), pp. 273–289.
24
[21] P. Vemuri, H. Wiste, S. Weigand, L. Shaw, J. Trojanowski, M. Weiner, D.S. Knopman,
R.C. Petersen, and C.R. Jack, MRI and CSF biomarkers in normal, MCI, and AD
subjects: predicting future clinical change, Neurology, 73 (2009), pp. 294–301.
[22] G. Wahba, Spline models for observational data, SIAM.
[23] J.L. Whitwell, S.A. Przybelski, S.D. Weigand, D.S. Knopman, B.F. Boeve, R.C. Pe-
tersen, and C.R. Jack, 3D maps from multiple MRI illustrate changing atrophy patterns
as subjects progress from mild cognitive impairment to Alzheimer’s disease, Brain, 130
(2007), pp. 1777–1786.
[24] W.Y.W. Yau, D.L. Tudorascu, E.M. McDade, S. Ikonomovic, J.A. James, D. Min-
has, W. Mowrey, L.K. Sheu, B.E. Snitz, and L. Weissfeld, Longitudinal assessment
of neuroimaging and clinical markers in autosomal dominant Alzheimer’s disease: a
prospective cohort study, The Lancet Neurology, 14 (2015), pp. 804–813.
[25] M. Yuan, and Y. Lin, Model selection and estimation in regression with grouped vari-
ables, Journal of the Royal Statistical Society: Series B (Statistical Methodology), 68
(2006), pp. 49–67.
[26] D. Zhang, D. Shen, and Alzheimer’s Disease Neuroimaging Initiative, Predicting future
clinical changes of MCI patients using longitudinal and multimodal biomarkers, PloS
One, 7 (2012), e33182.
25
